Salazar-Vizcaya, Luisa; Kouyos, Roger D; Fehr, Jan; Braun, Dominique; Estill, Janne Anton Markus; Bernasconi, Enos; Delaloye, Julie; Stöckle, Marcel; Schmid, Patrick; Rougemont, Mathieu; Wandeler, Gilles; Günthard, Huldrych F; Keiser, Olivia; Rauch, Andri (2018). On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study. Journal of viral hepatitis, 25(1), pp. 10-18. Blackwell Science 10.1111/jvh.12752
|
Text
Salazar-Vizcaya_et_al-2017-Journal_of_Viral_Hepatitis.pdf - Accepted Version Available under License Publisher holds Copyright. This is the peer reviewed version of the following article: Salazar-Vizcaya, Luisa; Kouyos, Roger D; Fehr, Jan; Braun, Dominique; Estill, Janne; Bernasconi, Enos; Delaloye, Julie; Stöckle, Marcel; Schmid, Patrick; Rougemont, Mathieu; Wandeler, Gilles; Günthard, Huldrych F; Keiser, Olivia; Rauch, Andri (2017). On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study. Journal of viral hepatitis, which has been published in final form at 10.1111/jvh.12752. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Download (601kB) | Preview |
|
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
Salazar-Vizcaya JViralHepat 2018.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (861kB) |
Increasing access to direct-acting antiviral (DAA)-treatment for hepatitis C virus (HCV) infection and decelerating the rise in high-risk behaviour over the next decade, could curb the HCV epidemic among HIV-positive men-who-have-sex-with-men (MSM). We investigated if similar outcomes would be achieved by short-term intensive interventions like the Swiss-HCVree-trial. We used a HCV-transmission model emulating two 12-months intensive-interventions combining risk-counselling with 1) universal DAA-treatment (pangenotypic intervention) and 2) DAA-treatment for HCV-genotypes 1 and 4 (replicating the Swiss-HCVree-trial). To capture potential changes outside intensive-interventions, we varied time from HCV-infection to treatment in clinical-routine and overall high-risk behaviour among HIV-positive MSM. Simulated prevalence dropped from 5.5% in 2016 to ≤2.0% over the intervention period (June/2016-May/2017) with the pangenotypic-intervention, and to ≤3.6% with the Swiss-HCVree-trial. Assuming time to treatment in clinical-routine reflected reimbursement restrictions (METAVIR ≥F2, 16.9 years) and stable high-risk behaviour in the overall MSM population, prevalence in 2025 reached 13.1% without intensive intervention, 11.1% with the pangenotypic intervention and 11.8% with the Swiss-HCVree-trial. If time to treatment in clinical-routine was 2 years, prevalence in 2025 declined to 4.8% without intensive-intervention, to 2.8% with the pangenotypic intervention, and to 3.5% with the Swiss-HCVree-trial. In this scenario, the pangenotypic intervention and the Swiss-HCVree-trial reduced cumulative (2016-2025) treatment episodes by 36% and 24% respectively. Therefore, intensive interventions could reduce future HCV-treatment costs and boost the benefits of long-term efforts to prevent high-risk behaviour and to reduce treatment delay. But if after intensive interventions treatment is deferred until F2, short-term benefits of intensive interventions would dissipate in the long-term. This article is protected by copyright. All rights reserved.
Actions (login required)
 |
Edit item |